Every material Form 8-K Ensysce Biosciences, Inc. has filed with the SEC since August 24, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ensysce Biosciences said director Will Chang intends to resign after the next annual meeting, and CEO Dr. Lynn Kirkpatrick will step down as CEO and take the title of Chief Operating Officer right after that meeting. President James Morrisson is set to become CEO at the same time, a change the company had previously reported, which gives shareholders a planned leadership transition.
Annual meeting scheduled for December 14, 2026; Kirkpatrick's title change and Chang's resignation take effect around it, and both would be delayed if the meeting is delayed.
James Morrisson, the company's President, will assume the title of Chief Executive Officer immediately after the annual meeting.
Kirkpatrick agreed to amend her September 14, 2021 employment offer letter so that taking the COO role will not trigger severance obligations.
Kirkpatrick has been CEO since January 2009 and also serves as CEO of EBIR, Inc., in which the company owns 79.2%.
Ensysce Biosciences said Nasdaq determined on August 25, 2026 that it complies with the $2.5 million stockholders' equity requirement, but the company remains subject to delisting if it does not evidence compliance in its next periodic report. Nasdaq also granted an extension on the minimum bid price rule to February 22, 2027, and said the Cy Biopharma transaction triggers a change of control requiring the post-transaction company to meet initial listing criteria, with trading suspension possible if it does not.
Nasdaq determined on August 25, 2026 that the company complies with the $2.5 million stockholders' equity requirement, but delisting remains possible if compliance is not evidenced in the next periodic report
Nasdaq granted an additional 180 calendar days, until February 22, 2027, to regain the $1.00 minimum bid price requirement
Nasdaq said the Cy Biopharma transaction, completed August 5, 2026, is a change of control requiring an initial listing application; failure could lead to trading suspension
The company intends to submit an initial listing application in a timely manner
Ensysce Biosciences said its first tranche of a Series C Preferred Stock financing, totaling roughly $43 million, closed on August 7, 2026, raising more than $21 million in gross proceeds. The company believes this restores compliance with Nasdaq's minimum stockholders' equity requirement and that it qualifies for a second 180-day grace period to regain compliance with the $1.00 bid price rule.
First tranche closed August 7, 2026, raising more than $21 million gross; total financing is about $43 million for 120,260 Series C Preferred shares
Second tranche depends on a clinical trial milestone that has not yet occurred
Company believes stockholders' equity is at least $2.5 million, meeting the Nasdaq Rule 5550(b)(1) requirement, pending Nasdaq confirmation
Second 180-day bid price grace period was requested from Nasdaq on August 24, 2026; Nasdaq response is pending
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ensysce Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →